What is BYSI's current stock price?

BYSI (BeyondSpring Inc.) is currently trading at $1.57 with a market cap of $64.6M.

What sector is BeyondSpring Inc. in?

BeyondSpring Inc. (BYSI) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

BYSI BeyondSpring Inc.

Healthcare

$1.57+9.03%ClosedMarket Cap: $64.6M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

-1.87

P/S

0.00

EV/EBITDA

-7.27

DCF Value

$0.18

FCF Yield

-29.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

23.8%

ROA

-41.5%

ROIC

-136.4%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-2.2M	$—
Q4 null	$0.00	$-2.1M	$—
FY null	$0.00	$-8.0M	$—
Q3 null	$0.00	$-1.5M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All

Huang Landirector, 10 percent owner, officer: Chief Executive Officer

SellFri May 15

Kirkby Matthewdirector

SellWed Apr 08

Xu Sihaidirector

SellFri Apr 03

Majeti Jiangwendirector

SellFri Apr 03

Lu Yingjuan Juneofficer: Chief Scientific Officer

SellFri Apr 03

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.41

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.

Peers